For Investors

The 21st century is being shaped by advances in the life sciences. From the ability to sequence human and other genes to more effective uses of gene, cell, and biologics therapy to the development of biological vaccines for COVID-19, malaria, and other diseases, biotechnology is moving faster than ever. At the same time, there are a lot of unmet medical needs, such as cancer, Alzheimer’s disease, AIDS, heart disease, and many others, that need urgent attention. Today’s life science industry is in a better position than ever before to take on these health problems.

But the need for biological therapies and vaccines is growing as fast as the costs and challenges of making them. Contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) are some of the more efficient and cost-effective alternatives to traditional pharmaceutical production that biotech companies are turning to. These smaller, more nimble organizations only do research and manufacturing. They are usually better able to meet sudden demands from an industry that is changing quickly.

This adaptability and quickness also make them more profitable. Synergy Biosciences, a CRO and consulting services provider, has a track record of helping both small and large biotech companies meet their business needs quickly and efficiently. It has grown in the last several years, along with the industry, but there are still more lucrative opportunities available for those who know what is coming. By teaming up with the right investors, Synergy can be in a better position to meet the needs of more clients and provide more diverse services.